Various IAP antagonists were reported to cooperate with TNF-related apoptosis inducing ligand (TRAIL; Apo2L) to kill carcinoma and leukemia cells in vitro and in vivo [26, 36-45]. Here, TNFSF10 is linked to carcinoma.